Figure 4. Charaterization of sept9a morphant and overexpression embryos.

Embryos were injected at the one-cell stage with morpholinos targeted to all sept9a transcripts (MO5), sept9a_tv1 only (MO2), mismatch controls (MO5MM, MO2MM), or sept9a_tv1 mRNA with and without MO2. Morphants shown were injected with 2.5 ng morpholino. At 48 hpf, the phenotypes were assessed by morphological criteria, according to severity. A,D: Class I morphants had defects in epidermal integrity and yolk extension and minor curvature of the tail. B,E: Class II morphants had a curved body axis in addition to the defects observed in class I. Class III morphants had a severely shortened body axis (data not shown). Arrows indicate yolk extension defects. All classes exhibited defects in blood circulation. G: Coinjection of 1 pg of sept9a_tv1 mRNA with 5 ng of MO2 partially rescued the observed phenotypes. H,I: Embryos injected with as little as 4 pg of sept9a_tv1 mRNA often had phenotypes similar to those of sept9a morphants including epidermal aggregates (arrow), blood pooling, and tail edema (bracket). (OE) indicates over expression. C,F: Control mismatch morpholinos did not present a phenotype. J: Graphical representation of MO classes at various concentrations. The number of embryos tested in each experiments is indicated by (n) on top of each column. K: sept9a splice morpholinos inhibit sept9a transcript splicing. RT-PCR analysis was performed on 24 hpf wild-type embryos, embryos injected with 2.5 ng MO5 or MO2 (pooled classes I and II), or 5 bp mismatch controls. MO5 embryos show a complete loss of sept9a_tv1 and sept9a_tv7. The presence of a low level of sept9a exons 3–5 transcripts in MO5-injected embryos may be due to maternal mRNA. MO2 embryos show a decrease in sept9a_tv1 compared to wild-type while the other transcripts are not affected.